Ulixacaltamide
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Ulixacaltamide
- Molecular weight
- 383.9
- Structure (SMILES)
- CC(C)(C)NC(=O)CN1CCC(CNC(=O)c2cc(F)cc(Cl)c2)CC1
- np 169944
- NP-169944
- np169944
- NP169944
- prax 944
- PRAX-944
- prax944
- PRAX944
- ulixacaltamide
- Ulixacaltamide
- ulixacaltamide [INN]
- ULIXACALTAMIDE [USAN]
- ulixacaltamide inn
- ulixacaltamide usan
- z 944
- Z-944
- z944
- Z944
- CAS registry numbers
- 1199236-64-0
- ChEMBL ID
- CHEMBL3934636
- InChIKey
- JOCLITFYIMJMNK-UHFFFAOYSA-N
- PubChem compound IDs
- 44540045
- FDA ingredient codes (UNII)
- QT2PJH89C3
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ulixacaltamide
- Type
- Synthetic organic
- Action
- Pore blocker
- Action type
- PORE_BLOCKER
- Target
- Cav3.1
- Gene symbol
- CACNA1G
- Protein identifier
- O43497
- Median affinity
- 7.3
- Affinity units
- pIC50
- Action
- Pore blocker
- Action type
- PORE_BLOCKER
- Target
- Cav3.2
- Gene symbol
- CACNA1H
- Protein identifier
- O95180
- Median affinity
- 6.8
- Affinity units
- pIC50
- Action
- Pore blocker
- Action type
- PORE_BLOCKER
- Target
- Cav3.3
- Gene symbol
- CACNA1I
- Protein identifier
- Q9P0X4
- Median affinity
- 7
- Affinity units
- pIC50
Investigated indications
- Condition
- Essential Tremor
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003108
- Subject identifier
- D020329
- Condition identifier
- EFO_0003108
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003233
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 2
- Polar surface area
- 61.44
- Calculated partition coefficient (ALogP)
- 2.84
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 26
- Molecular formula
- C19H27ClFN3O2
- Monoisotopic mass
- 383.1775830
- Natural product
- No
- Recorded assays
- 13
- Active assays
- 12
- Confirmatory
- Other
- Calcium Channel Blockers
Related records
Trials (3)
- A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial of PRAX-944 in Participants With Essential Tremor
- Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
In development for (1)
- Essential tremor Phase 1